Posters

Preliminary visual and clinical outcomes in femtosecond laser-assisted cataract surgery: a single-center retrospective cohort analysis of 200 eyes in Turkey

Poster Details

First Author: C.Yildirim TURKEY

Co Author(s):    H. Aslankara   A. Dvallishvilli   A. Kocakaya              

Abstract Details

Purpose:

To assess the safety, efficacy and preliminary results of femtosecond laser-assisted cataract surgery (FLACS) in Turkish patients.

Setting:

Single-center private Gozakademi Eye Hospital, Denizli, Turkey

Methods:

The clinical records of first 200 consecutive eyes of 144 Turkish patients who underwent FLACS using the Catalys (Optimedica, SantaClara, CA, USA) platform between January and October 2016 were reviewed. FLACS involved anterior capsulotomy, lens fragmentation, corneal incisions and intrastromal non-penetrating astigmatic keratotomies when needed based on optical coherence tomography-guided treatment mapping and completed by standard 2.2 mm phacoemulsification and insertion of an intraocular lens. Data were collected retsospectively about patient demographics, preoperative investigations, intra- and postoperative complications and postoperative visual and clinical outcomes at 1 year follow-up.

Results:

Multiple docking attempts were required in 14.5% of eyes, while suction loss occured in 1 eye. Small and uneventful anterior capsular tags were detected in 16 eyes (8%). No capsuler blockage syndrome, posterior capsule rupture or drooped nucleus were observed. Subconjunctival hemorrhage occured in 70 eyes (35%). Miosis occured after the laser procedure in 60 eyes(30%). YAG laser capsulotomy was applied in 19 eyes (9.5%). Cystoid macular edema occured in 1 eye (0.5%). The mean best corrected visual distance acuity at baseline was 0,65±0,39 logMAR unit, after the surgery at first year was 0,07±0,1 logMAR unit (p=0.03).

Conclusions:

FLACS appears to be safe and may allow greater efficiency and decreased postoperative complications. Further research is needed into long-term safety aspects such as posterior capsule opacification and cystoid macular edema.

Financial Disclosure:

None